In short
Clinical trials investigating Anidulafungin are studying how it is used in serious fungal infections, especially candidemia and invasive candidiasis, and also as part of treatment plans for other severe infections. These studies look at safety, effectiveness, and treatment length in adult patients with different infection types.
Key points
- Clinical trials involving Anidulafungin are focused on serious fungal infections, especially candidemia and invasive candidiasis, and one study also includes invasive mold infections. All of the listed studies are Phase 3 trials, which means they are testing treatments in larger patient groups. The target populations are mainly adults with severe or complicated fungal infections, and one trial focuses on uncomplicated candidemia. The studies measure outcomes such as all-cause mortality, treatment response, and how long patients need broad-spectrum antibiotics. One trial also tests whether a shorter treatment course after the first negative blood culture can work as well as a longer course. These trials compare Anidulafungin with other antifungal or treatment strategies to see which approach performs best.
Clinical trials overview
All of the trials listed for Anidulafungin are Phase 3 studies, which means they are testing treatments in larger groups of patients to learn more about benefit and safety in real-world use.
These are interventional studies, so researchers are assigning treatment plans and comparing results between groups.
The studies focus on adults with serious fungal infections, especially candidemia, invasive candidiasis, and invasive mold infections.
Trials in candidemia and invasive candidiasis
One completed Phase 3 trial studied adults with invasive candidiasis/candidemia and compared two treatment paths: an intravenous echinocandin followed by oral ibrexafungerp versus an intravenous echinocandin followed by oral fluconazole or best available therapy.
Anidulafungin was one of the intravenous echinocandin options used in this study.
The main outcome was all-cause mortality at Day 30, and the study also measured successful global response at the end of treatment in the EU population.
A second Phase 3 trial, called CANDISHORT, studied adults with uncomplicated candidemia and compared a shorter treatment course with a longer one after the first negative blood culture.
In this trial, Anidulafungin was one of several antifungal medicines used in the treatment options being tested.
The main endpoint was all-cause mortality at Day 28 after the first negative blood test, with a small time window of plus or minus 2 days.
Trial in invasive mold infections
One authorised Phase 3 study is testing fosmanogepix in adults with invasive mold infections caused by Aspergillus species, Fusarium species, Lomentospora prolificans, Mucorales fungi, or other multidrug resistant molds.
Anidulafungin appears in the list of antifungal treatments used in the study treatment options, showing that it is part of the broader comparison set.
The trial plans to enroll 210 participants and measures Day 42 all-cause mortality as the primary outcome.
This study is important because it focuses on infections that are difficult to treat and may have limited treatment choices.
Trial in severe infections and antibiotic use
The MODIFY trial is a Phase 3 study in adults with severe infections.
Its goal is not mainly to test Anidulafungin alone, but to see whether a strategy using procalcitonin guidance and molecular-guided diagnosis can reduce the number of days patients receive empirical broad-spectrum antibiotics.
Anidulafungin is included among the treatment options in this trial’s intervention list.
The primary outcome is the number of days under treatment with broad-spectrum antibiotics in the MODIFY group compared with standard care.
The trial plans to enroll 190 participants.
Main outcomes being measured
The trials use outcomes that help show whether treatment is working and whether patients survive the infection.
- All-cause mortality: this means death from any cause during the study period, and it is used in several of the trials.
- Successful global response: this is a combined measure of how well the infection responds to treatment by the end of treatment.
- Days on broad-spectrum antibiotics: this measures how long patients need wide-coverage antibiotics, which is the key outcome in the MODIFY trial.
- Time after the first negative blood culture: this is used in the CANDISHORT study to compare shorter and longer treatment durations.
What patients should know about these studies
These studies are designed for adults with serious fungal infections, and one study also includes adults with severe infections more broadly.
Some trials compare Anidulafungin with other antifungal medicines, while others use it as part of a treatment strategy being tested against standard care.
The studies are trying to answer practical questions such as which treatment works best, how long treatment should last, and whether patients can do well with fewer days of broad-spectrum antibiotics.
Because these are Phase 3 studies, they are meant to give stronger evidence about treatment results in larger patient groups.